Evidence Synthesis
Here is the rewritten narrative: PPLPHARMA's gross margin has accelerated to 59.42%, up from a negative 1.25%.
The company's marginal operating leverage has turned positive, standing at . Revenue growth has been strong, rising by year-over-year.
Earnings per share (EPS) have declined to , down from -0.7191 INR. EPS surprise percentage has improved to , up from -8.588%.
Daily volume has decreased to 4,572,376 shares, down from 7,524,546 shares. The close price has decreased to , down from 216.66 INR. Analysts have a target price premium of . News sentiment has been positive, with a score of 0.82.